Stevens-Johnson syndrome and toxic epidermal necrolysis: Efficacy of intravenous immunoglobulin and a review of treatment options

Singapore Medical Journal

Volumn 50, Issue 1, 2009, Pages 29-33

  Teo, L ^a   Tay, Y K ^a   Liu, T T ^a   Kwok, C ^a  

^a CHANGI GENERAL HOSPITAL   (Singapore)

Author keywords

Adverse drug reaction; Corticosteroids; Intravenous immunoglobulin; Stevens Johnson syndrome; Toxic epidermal necrolysis

Indexed keywords

ALLOPURINOL; AMOXICILLIN; CARBAMAZEPINE; CIPROFLOXACIN; IMMUNOGLOBULIN; PENTOXIFYLLINE; PREDNISOLONE; TEICOPLANIN;

ADULT; AGED; ANAMNESIS; ARTICLE; BACTERIAL SKIN DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; EPIDERMOLYSIS; FEMALE; HUMAN; MALE; PUNCH BIOPSY; RAYNAUD PHENOMENON; SCHIZOPHRENIA; STEVENS JOHNSON SYNDROME; URINARY TRACT INFECTION;

ADULT; AGED; AGED, 80 AND OVER; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EPIDERMAL NECROLYSIS, TOXIC; FATAL OUTCOME; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MALE; MIDDLE AGED; STEVENS-JOHNSON SYNDROME;

EID: 62649137587     PISSN: 00375675     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Roujeau JC, Huynh TN, Bracq C, et al. Genetic susceptibility to toxic epidermal necrolysis. Arch Dermatol 1987; 123:1171-3.
2. Hung SI, Chung WH, Jee SH, et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharm Genom 2006; 16:297-306.
3. Nassif A, Bensussan A, Boumsell L, et al. Toxic epidermal necrolysis: effector cells are drug-specifc cytotoxic T cells. J Allergy Clin Immunol 2004;114:1209-15.
4. Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998; 282:490-3.
5. Chang HY, Cooper ZA, Swetter SM, Marinkovich MP. Kinetics and specificity of Fas ligand infuction in toxic epidermal necrolysis. Arch Dermatol 2004; 140:242-4.
6. Chave TA, Mortimer NJ, Sladden MJ, Hall AP, Hutchinson PE. Toxic epidermal necrolysis: current evidence, practical management and future directions. Br J Dermatol 2005; 153:241-53.
7. Park GT, Quan G, Lee JB. Sera from patients with toxic epidermal necrolysis contain autoantibodies to periplakin. Br J Dermatol 2006; 155:337-43.
8. Paquet P, Kaveri S, Jacob E, et al. Skin immunoglobulin deposition following intravenous immunoglobulin therapy in toxic epidermal necrolysis. Exp Dermatol 2006; 15:381-6.
9. Yeung CK, Lam LK, Chan HH. The timing of intravenous immunoglobulin therapy in Stevens-Johnson syndrome and toxic epidermal necrolysis. Clin Exp Dermatol 2005; 30:600-2.
10. Shortt R, Gomez M, Mittman N, Cartotto R. Intravenous immunoglobulin does not improve outcome in toxic epidermal necrolysis. J Burn Care Rehabil 2003; 24:S88.
11. Brown KM, Silver GM, Halerz M, Walaszek PS, Gamelli RL. Toxic epidermal necrolysis syndrome: does IgG make a difference? J Burn Care Rehabil 2003; 24:S87.
12. Bachot N, Revuz J, Roujaeu J-C. Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis. Arch Dermatol 2003; 139:33-6.
13. Tan AW, Thong BY, Yip LW, Chng HH, Ng SK. High-dose intravenous immunoglobulins in the treatment of toxic epidermal necrolysis: An Asian series. J Dermatol 2005; 32:1-6.
14. Tegelberg-Stassen MJAM, van Vloten WA, Baart de la Faille H. Management of nonstaphylococcal toxic epidermal necrolysis: Follow-up study of 16 case histories. Dermatologica 1990; 180:124-9.
15. Vecchietti G, Kerl K, Prins C, et al. Severe eczematous skin reaction after high-dose intravenous immunoglobulin infusion: report of 4 cases and review of the literature. Arch Dermatol 2006; 142:213-7.
16. Hebert AA, Bogle MA. Intravenous immunoglobulin prophylaxis for recurrent Stevens-Johnson syndrome. J Am Acad Dermatol 2004; 50:286-8.
17. Hunger RE, Hunziker T, Buettiker U, Braathen LR, Yawalkar N. Rapid resolution of toxic epidermal necrolysis with anti-TNF- alpha treatment. J Allergy Clin Immunol 2005; 116:923-4.
18. Fischer M, Fiedler E, Marsch WC, Wohlrab J. Antitumor necrosis factor-alpha antibodies (infiximab) in the treatment of a patient with toxic epidermal necrolysis. Br J Dermatol 2002; 146:707-9.
19. Khalili B, Bahna SL. Pathogenesis and recent therapeutic trends in Stevens- Johnson syndrome and toxic epidermal necrolysis. Ann Allergy 2006; 97:272-81.
20. Trautmann A, Klein CE, Kampgen E, Brocker EB. Severe bullous drug reactions treated successfully with cyclophosphamide. Br J Dermatol 1998; 139:1127-8.
21. Egan CA, Grant WJ, Morris SE, et al. Plasmapheresis as an adjunct treatment in toxic epidermal necrolysis. J Am Acad Dermatol 1999; 40:458-61.
22. Nomura T, Abe R, Fujimoto K, et al. Plasma exchange; a promising treatment for toxic epidermal necrolysis with AIDS. AIDS 2004; 18:2446-8.
23. Redondo P, de Felipe I, de la Pena A, et al. Drug induced hypersensitivity syndrome and toxic epidermal necrolysis. Treatment with N-acetylcysteine. Br J Dermatol 1997; 136:645-6.
24. Wolkenstein P, Latarjet J, Roujeau JC, et al. Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet 1998; 352:1586-9.
25. Bastuji-Garin S, Fouchard N, Berticchi M, et al. SCORTEN: A severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol 2000; 115:149-53.